SFM
CPRX

Signet Financial Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Signet Financial Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,000
Closed -$6K – 987
2018
Q2 		$6K Hold
2,000
– – ﹤0.01% 686
2018
Q1 		$5K Buy
+2,000
New +$6.65K ﹤0.01% 661

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Signet Financial Management's CPRX Position: Q3 2018 in Review

Signet Financial Management sold out of Catalyst Pharmaceutical (CPRX) in Q3 2018, closing a stake of 2,000 shares — an estimated $6K sold.

Signet Financial Management first reported a position in CPRX in Q1 2018 and held it in 2 quarters. The position peaked at $6K in Q2 2018. 97 funds tracked by Wall St. Rank hold CPRX as of Q3 2018.

  • Signet Financial Management reported no remaining Catalyst Pharmaceutical position as of Q3 2018 after selling out during the quarter.
  • Signet Financial Management sold 2,000 Catalyst Pharmaceutical shares in Q3 2018, an estimated $6K.
  • Signet Financial Management first reported a position in Catalyst Pharmaceutical in Q1 2018 and held it in 2 quarters.
  • Signet Financial Management's Catalyst Pharmaceutical position peaked at $6K in Q2 2018.
  • 97 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2018.

Based on Signet Financial Management's 13F filing for Q3 2018, filed 14 Nov 2018.